Gyre Therapeutics, Inc. (GYRE)

USD 7.72

(2.66%)

Market Cap (In USD)

662.54 Million

Revenue (In USD)

113.45 Million

Net Income (In USD)

-92.93 Million

Avg. Volume

139.82 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
8.26-30.4
PE
154.4
EPS
0.05
Beta Value
0.0
ISIN
US4037831033
CUSIP
-
CIK
1124105
Shares
86332200.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Han Ying Ph.D.
Employee Count
-
Website
https://www.gyretx.com
Ipo Date
2006-04-12
Details
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.